What happens when world-leading science connects with the power of American innovation? 

Imperial is the only international university with a permanent base in the San Francisco Bay Area, Imperial Global USA, which US collaborators are using to gain a direct gateway to our research and pipeline of deep technology startups. 

Developments in the last month show the traction Imperial technologies are gaining in the US. Pfizer announced a $5 billion bet on obesity drug candidates from Imperial, and CoreWeave, a global leader in cloud computing, acquired Imperial spinout Monolith to dramatically scale its AI solutions for engineers.

Imperial’s startups, born from our world-leading research and education, are becoming ready for investments and exits due partly to the entrepreneurship support and the infrastructure we’re expanding in West London. We highlighted some of these ecosystem developments at an event last week with Vinod Khosla, founder of Khosla Ventures, and in September a panel discussion celebrating the UK-US tech agreement.

And through initiatives such as Venture Treks, which take founders to major technology and life sciences centres to meet investors and industry leaders, we’re helping our international collaborators to access these emerging businesses. 

For our partners from the UK and other countries, transatlantic connections open opportunities to build visibility in the US, and access collaboration from global leaders. By engaging with us, companies can connect with networks that accelerate growth on both sides of the Atlantic. 

Get involved

Venture Catalyst Challenge 

Watch the Venture Catalyst Challenge Grand Final online as five finalist teams pitch their groundbreaking ideas to industry-leading judges. Imperial’s flagship pre-accelerator showcases innovations developed through an intensive three-month programme. 

6 November, available online

How to create value

Business leaders, policymakers and academics will gather at the 8th Global Conference on Creating Value to explore value creation in fast-evolving sectors like aviation and health tech, featuring speakers from Accenture, AstraZeneca and leading universities.

19 November in South Kensington 

Next in technology

A compound from Imperial could prove safer and more effective than current GLP-1 drugs, clinical trials suggest. Pfizer has placed a $4.9 billion dollar bet on the drug candidate and others from Imperial after it agreed to acquire Metsera, a biotechnology company developing drug candidates invented by GLP-1 pioneer Professor Steve Bloom.

Nasal sprays could stop viruses in their tracks

Vaccines delivered to mucous membranes such as in the inside of the nose can trigger a strong immune response at the site an infection enters the body. Research with AstraZeneca and the UK Health Security Agency aims to better understand mucosal immunity and support the development of new vaccines..

Fertility clues to be found in menstrual blood 

Tests on menstrual blood could help women understand their reproductive health for purposes such as in vitro fertilisation (IVF). Alumnus startup Genie Fertility is using AI to find biomarkers that could provide detailed information without invasive biopsies, and has raised pre-seed funding to develop its approach.

AI is solving tough engineering problems 

A platform from Imperial AI company Monolith has helped engineers at leading companies in sectors such as automotive, aerospace and batteries solve complex problems – and will now become part of the product offering from CoreWeave, a cloud computing company that has acquired the spinout.

Green hydrogen cost could be reduced 30% 

High-surface area metal sheets made using techniques traditionally used for manufacturing plastics could increase the efficiency of the reactions that produce hydrogen, and reduce the cost of turning renewable electricity into hydrogen fuel. The spinout developing the technique, M-Spin, has opened a pilot lab.

Collaborate. 

Explore.

Innovate.

Stay in touch

To explore how Imperial Enterprise
could help your business benefit from
Imperial’s world-leading expertise,
technologies, resources and talented
innovators, view our LinkedIn, website
or drop us a line today.

Been forwarded this newsletter? Subscribe here

You have received this email because you subscribed to the Enterprise Newsletter or agreed to receive communications from Imperial Enterprise.

This email was sent from enterprise@imperial.ac.uk

Copyright © Imperial College London, All rights reserved.